| Cell line name |
HCC78 ROS1 p.L2026M |
|---|
| Accession |
CVCL_E6J2 |
|---|
| Resource Identification Initiative |
To cite this cell line use: HCC78 ROS1 p.L2026M (RRID:CVCL_E6J2) |
|---|
| Comments |
Population: Caucasian.
Characteristics: Shows significant resistance towards crizotinib (PubMed=38433235).
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. |
|---|
| Sequence variations |
- Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:11020; SLC34A2; Name(s)=SLC34A2-ROS1 (from parent cell line).
- Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:10261; ROS1; Simple_edited; p.Leu2026Met (c.6076C>A); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=38433235).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Lung adenocarcinoma (NCIt: C3512) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_2061 (HCC78) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
65Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | DOI=10.63028/10067/2105480151162165141
Terrones M.
Profiling targeted therapy responses in ROS1+ non-small cell lung cancer using genomically engineered patient-derived cell lines.
Thesis PhD (2024); University of Antwerp; Antwerp; Belgium PubMed=38433235; DOI=10.1186/s12967-024-04988-0; PMCID=PMC10910754
Terrones M., Deben C., Rodrigues-Fortes F., Schepers A., Op de Beeck K., Van Camp G., Vandeweyer G.
CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
J. Transl. Med. 22:234.1-234.16(2024) |
|---|
| Entry history |
|---|
| Entry creation | 10-Apr-2025 |
|---|
| Last entry update | 10-Apr-2025 |
|---|
| Version number | 1 |
|---|
